Amfetamine modified release - Highland Therapeutics

Drug Profile

Amfetamine modified release - Highland Therapeutics

Alternative Names: D-amphetamine sulfate capsules; Dexamfetamine modified release - Highland Therapeutics; Dextroamphetamine sulfate modified release - Highland Therapeutics; HLD 900; HLD-100

Latest Information Update: 21 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Highland Therapeutics
  • Developer Highland Therapeutics; Ironshore Pharmaceutical and Development
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder
  • Clinical Phase Unknown Bulimia nervosa

Most Recent Events

  • 12 Apr 2017 Ironshore Pharmaceuticals announces intention to submit NDA to the US FDA for Attention deficit hyperactivity disorder in 2018
  • 12 Apr 2017 Safety and efficacy data from a phase II trial in Attention deficit disorder released by Ironshore Pharmaceuticals
  • 12 Apr 2017 Ironshore Pharmaceuticals plans pivotal phase III trials for Attention deficit hyperactivity disorder in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top